Is Bristol-Myers Squibb Co halal to invest in?

As of August 2026, Bristol-Myers Squibb Co BMYS.VI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Bristol-Myers Squibb Co a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Bristol-Myers Squibb Co using these criteria to determine its compliance status.

Can Muslims buy shares of Bristol-Myers Squibb Co?

Muslim investors may consider investing in Bristol-Myers Squibb Co if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Bristol-Myers Squibb Co classified as NOT HALAL?

Musaffa determines the Shariah status of Bristol-Myers Squibb Co by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Bristol-Myers Squibb Co updated?

The Shariah compliance status of Bristol-Myers Squibb Co may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Bristol-Myers Squibb Co become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Bristol-Myers Squibb Co?

You can check the latest Shariah compliance status of Bristol-Myers Squibb Co on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Bristol-Myers Squibb Co BMYS.VI

Last Updated: Aug 12, 12:00 AM·WBAG

BMYS.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Bristol-Myers Squibb Co is classified as not halal.

NOT HALAL

Report Source: undefined Quarter Report

Bristol-Myers Squibb Co. Stock Analysis BMYS.VI

Austria Health Care Large Cap

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).